more than 30 new product at various stages of registration that were carefully selected in order to address many un-met therapeutic needs, such as high prevalence diseases and other diseases of high national interest. Amoun’s product portfolio and product pipeline will endure further expansions for many years to come and will continue to play a major role in driving growth and in increasing shareholders’ value.